TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04567836

Intervention type: OTHER
Intervention: Investigation of the prevalence of test positivity
Description: The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses .

Intervention type: OTHER
Intervention: Investigation of the prevalence of test positivity
Description: The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses .
Study: NCT03692273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Luminis ultrapulse fractional ablative carbon dioxide laser
Description: This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.5mm punch biopsy
Description: punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
Study: NCT00659438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: 300mg orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bicalutamide
Description: 150mg orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once daily
Study: NCT03560895

Intervention type: DEVICE
Intervention: cuffed endotracheal tube
Description: Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube

Intervention type: DEVICE
Intervention: Uncuffed endotracheal tube
Description: Patients will be anesthetized using uncuffed endotracheal tube
Study: NCT05109390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Chewable tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum/Magnesium Hydroxide/Simethicone
Description: Chewable tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral, delayed-release capsule.
Study: NCT05955742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: The operator prepared the glide path using a #15K-type stainless-steel hand file.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProGlider
Description: The operator prepared the glide path using the ProGlider file.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveOne Gold Glider
Description: The operator prepared the glide path using the WaveOne Gold Glider file.
Study: NCT01432639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program
Description: The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
Study: NCT03501212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Anesthetic
Description: EMLA Cream 2.5 gr applied to both wrists

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Cream 2.5gr applied to both wrist
Study: NCT00834119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
Study: NCT02119208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity and timing of exercise
Study: NCT02164565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) treatment
Description: Tranexamic Acid (TXA) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control grup: without Tranexamic Acid (TXA) treatment.
Description: control grup: without Tranexamic Acid (TXA) treatment.
Study: NCT02201823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812. Five cohorts and one extension phase.
Study: NCT03094247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: All patients with severe acute malnutrition will receive a course of amoxicillin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: All patients with severe acute malnutrition will receive a course of amoxicillin.
Study: NCT02767791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study: NCT03094247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: All patients with severe acute malnutrition will receive a course of amoxicillin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HO-RUTF
Description: HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-HO-RUTF
Description: D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUTF
Description: S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
Study: NCT02767791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy
Description: Auriculotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: Auriculotherapy
Study: NCT01020474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 75-450mg/day pregabalin dose optimised at start of study
Study: NCT03058003

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography Evaluation
Description: Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography Evaluation
Description: Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended

Intervention type: OTHER
Intervention: Central Sensitization Inventory
Description: Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)

Intervention type: OTHER
Intervention: Central Sensitization Inventory
Description: Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
Study: NCT03872128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone300
Description: 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone500
Description: 500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03998150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar plasma kinetic enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
Study: NCT03296722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Transtheoretical Model
Description: Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
Study: NCT00856167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Description: whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care for TMD
Description: a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
Study: NCT03285594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Antidiabetes Drugs (OADs)
Description: OADs (including metformin) as prescribed by the investigator as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antidiabetes Drugs (OADs)
Description: OADs (including metformin) as prescribed by the investigator as per local labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antidiabetes Drugs (OADs)
Description: OADs (including metformin) as prescribed by the investigator as per local labeling.
Study: NCT02213263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280586
Description: PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Description: MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
Study: NCT01673672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT003
Description: 7 subcutaneous injections, weekly/biweekly within 10 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT003
Description: 7 subcutaneous injections, weekly/biweekly within 10 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT003
Description: 7 subcutaneous injections, weekly/biweekly within 10 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 subcutaneous injections, weekly/biweekly within 10 weeks
Study: NCT00688779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Concentrate for nasal spray,solution 60 mg/g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01105130

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03314168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
Study: NCT01105130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-Arginine
Description: Given orally 3 capsules ArginMax and 3 Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-Arginine
Description: Given orally 3 capsules ArginMax and 3 Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-Arginine
Description: Patients will take 6 capsules of ArginMax twice daily
Study: NCT05016336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social interaction combined with cognitive training based on mnemonic strategies.
Description: In the first six sessions, participants in the experimental group learned and practiced six different mnemonic strategies: Story-Formation strategy, Face-Name strategy, Peg-Word strategy, Chunking strategy, Key-Word strategy and the Method of Loci. In the following six sessions, in order to assimilate the strategies they learned, participants practiced the same tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction group
Description: In the control group, each session also began with a conversation between the participants. The sessions then dealt with the content of interpersonal communication and the acquisition of tools for creating interpersonal relationships. Participants were asked to share the way they used the tools they acquired between sessions and received feedback from the other participants
Study: NCT02274428

Intervention type: DRUG
Group type: OTHER
Intervention: pneumostem
Description: human umbilical cord blood derived mesenchymal stem cells
Study: NCT00856102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-base walking program

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Control
Description: Usual care
Study: NCT02463877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-Invasive Procedure
Description: Laparoscopy
Study: NCT00739570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AAI signature IV AMCT
Description: Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
Study: NCT04137887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
Study: NCT00552903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Personal health coach providing advice and counselling by telephone, weekly contacts
Study: NCT01371760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous PTA
Description: PTA of the internal jugular and/or azygous vein

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Catheter Venography
Description: The patients will undergo catheter venography but not PTA
Study: NCT04764539

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Assisted Speech Therapy (VAST)
Description: Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Assisted Speech Therapy (VAST)
Description: Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
Study: NCT00218894

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: surgery one one or two eyes by use of two different types of lenses and correcting for refraction
Study: NCT00368849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
Study: NCT00224718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular repair (with endograft)
Description: An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair
Description: Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
Study: NCT01344863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 600 mg subcutaneously using a single-use injection device on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab [Herceptin]
Description: 600 mg subcutaneously using a handheld syringe on Day 1
Study: NCT04571684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITSystem 2.1
Description: HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
Study: NCT01910753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APA
Description: A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
Study: NCT02102815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: NSS 50 mL IV slowly push over 5 minutes
Study: NCT02412553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific carbohydrate diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elemental diet